Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories) - Global Industry Insights, and Forecast to 2025

Cancer Biomarkers Market – Insights

Cancer biomarkers are biological molecule produced either by tumor cells or by human tissues in response to cancer, which then measured and evaluated as an indicator of cancerous processes within the body. Cancer biomarkers are extensively used in detection and management of patients with cancer. In patients, who undergone curative surgery for cancer, biomarkers are used in follow-up surveillance and for early detection of possible recurrent disease. Moreover, continuous advancements in cancer diagnosis includes use of molecular biomarkers as part of routine diagnostic tests. Molecular alterations used for cancer diagnosis involves application of DNA, RNA, microRNAs, and proteins. Governments of various countries are focusing on investing in prevention and early intervention of cancer, to reduce emotional and physical impact of cancer on patients and their families. Moreover, national healthcare departments are involved in continuous development in cancer research and treatment. Increasing incidence of cancer is expected to lead to innovation and development in the area of cancer diagnosis with biomarker. For instance, according to the 2015 data findings, U.K. Department of Health & Social Care invests US$ 7.5 billion on cancer related treatment and services, annually.

The global cancer biomarkers market was valued at US$ 11.6 billion in 2017 and is expected to witness a CAGR of 14.2% over the forecast period (2017–2025).

Global Cancer Biomarkers Market Share (%), By Biomarker Type, 2017 & 2025

cancer biomarkers market

Source: Coherent Market Insights Analysis (2018)

Growing Research and Development Funding from Various Government and Private Organizations is a Factor Driving Growth of the Cancer Biomarkers Market

Various government and private organizations are focusing on increasing investment in R&D for cancer biomarkers. This is owing to increasing incidence and prevalence of cancer, globally. For instance, in June 2018, Cancer Research UK, proposed funding of US$ 140,922 per year, through biomarker project for biomarker assay development, validation, and qualification for use in cancer clinical diagnosis. Furthermore, in March 2016, the National Cancer Institute (NCI) invested US$ 5.5 million in 2016, for setting up of laboratories to conduct research on biomarkers and biomarker assays for cancers of the breast, prostate, lung, and genitourinary organs, and also to those cancers, which have high incidence rate. In April 2016, University of Auckland received a US$ 10 million grant to conduct research in cancer biomarkers, from Auckland entrepreneur, Mr Liangren Li and his family. The grant was allocated for initiating the PROSPER (Profiling of Oncology Patients as part of Clinical care and Research) project. In 2016, National Cancer Institute (NCI) invested US$ 3.9 billion for cancer research activities, which accounts for 70.8% of overall NCI 2016 budget. It invested around US$ 533 million on cancer detection and diagnostic research activities. Moreover, in 2016, NCI allocated 40.4% of its funds for Research Project Grants (RPGs). Furthermore, in 2017, NCI budget increased by US$ 454 million (8.7%) from previous year (2016) for cancer research activities. These increasing research and development (R&D) activities in biomarkers is expected augment growth of global cancer biomarkers market.

High Prevalence and Incidence of Cancer is expected to Drive Growth of the Cancer Biomarkers Market

Breast cancer is the second most common type of cancer in the U.S., after skin cancer. Breast cancer can occur both, in men and women. However, it is mostly found among females and the male occurrence of breast cancer is very rare. According to the Centers for Disease Control and Prevention (CDC), in 2014, 236,968 women and 2,141 men in the U.S. were diagnosed with breast cancer, while 41,211 women and 465 men in the U.S. died from breast cancer. According to the Cancer Research U.K., 2015 statistics, 55,122 new cases of breast cancer were registered in 2015, in the U.K. Moreover, according to the similar source, in U.K., breast cancer is the most common cancer, which accounted for 15% of all new cancer cases in 2015.

According to the International Agency for Research on Cancer (IARC), in 2012, an estimated 14.1 million new cancer cases were reported. Among these, the most common form of cancer was lung cancer (13%), breast cancer (11.9%), and colorectal cancer (9.7%). According to the World Cancer Research Fund (WCRF) International, 2015 data findings, 58% of the lung cancer cases were reported in emerging economies, in 2014. Hungary had the highest rate of lung cancer, followed by Serbia, and North Korea. Moreover, highest incidence of lung cancer was registered in North America and Europe, for the same year. According to the National Cancer Institute, in 2014, around 66,771 people were suffering from liver and intrahepatic bile duct cancer in the U.S. Liver and intrahepatic bile duct cancer represented 2.4% of all new cancer cases reported in the U.S. in 2014. Moreover, obesity, diabetes, alcoholic liver disease (cirrhosis), chronic hepatitis B, hepatitis C infections, tobacco, and smoking are the most common risk factors for liver cancer. According to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, each year in the U.S., around 22,000 men and 9,000 women suffer from liver cancer, and around 16,000 men and 8,000 women die from liver cancer. Thus, substantial increase in incidence and mortality rate of liver cancer in the country, is expected to boost growth of cancer biomarkers market, in the near future. 

However, high treatment cost and unfavorable reimbursement policies for cancer biomarkers is a factor hindering growth of the cancer biomarkers market. Cancer diagnosis is relatively expensive, which primarily includes medical and non-medical costs for cancer diagnosis, treatment, and cancer care. For instance, according to the Cancer Action Network, in 2014, cancer patients in the U.S. paid around US$ 4 billion out-of-pocket for cancer treatment. In addition to this, around US$ 87.8 billion was spent in 2014, in the U.S., on cancer-related health care.

Key players operating in the cancer biomarkers market include BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.

Cancer biomarkers offers great opportunity in improving management of cancer patients by enhancing the efficiency of detection and efficacy of the treatment. Biomarkers of cancer includes various biochemical components such as proteins, sugars, lipids, nucleic acids, and small metabolites, cytogenetic and cytokinetic parameters, and whole tumor cells, which are found in body fluid. Increasing research and development activities in the field of cancer biomarker to develop and identify potential cancer biomarkers for early diagnosis of cancer, will lead to the growth of cancer biomarkers market, in the near future. For instance, in March 2018, a team of researchers from University of Massachusetts and Clarkson University discovered various protein such as human chorionic gonadotropin (hCG), lipoproteins, α1-chymotrypsin and α1-antitrypsin from breast milk, which can act as a potential cancer biomarker in detection of breast cancer.

Market Dynamics

The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. For instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in emerging economies. However, high cancer treatment cost and unfavorable reimbursement policies for cancer biomarker may hinder the growth of cancer biomarkers market.

Key features of the study:

  • This report provides in-depth analysis of the cancer biomarkers market and its market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global cancer biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion and marketing tactics.
  • The global cancer biomarkers market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for cancer biomarkers market, research and consulting firms, new entrants and financial analysts.

Detailed Segmentation:

  • Global Cancer Biomarkers Market, By Biomarker Type:
    • Protein Biomarkers
    • Genetic Biomarkers
    • Other Cancer Biomarkers
  • Global Cancer Biomarkers Market, By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Prostate Cancer
    • Kidney Cancer
    • Liver Cancer
    • Other Cancers
  • Global Cancer Biomarkers Market, By End User:
    • Hospitals
    • Academic and Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Cancer Diagnostic Laboratories
  • Global Cancer Biomarkers Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Biomarker Type:
        • Protein Biomarkers
        • Genetic Biomarkers
        • Other Cancer Biomarkers
      • By Cancer Type:
        • Breast Cancer
        • Lung Cancer
        • Prostate Cancer
        • Kidney Cancer
        • Liver Cancer
        • Other Cancers
      • By End User:
        • Hospitals
        • Academic and Cancer Research Institutes
        • Ambulatory Surgical Centers
        • Cancer Diagnostic Laboratories
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Biomarker Type:
        • Protein Biomarkers
        • Genetic Biomarkers
        • Other Cancer Biomarkers
      • By Cancer Type:
        • Breast Cancer
        • Lung Cancer
        • Prostate Cancer
        • Kidney Cancer
        • Liver Cancer
        • Other Cancers
      • By End User:
        • Hospitals
        • Academic and Cancer Research Institutes
        • Ambulatory Surgical Centers
        • Cancer Diagnostic Laboratories
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
      • By Biomarker Type:
        • Protein Biomarkers
        • Genetic Biomarkers
        • Other Cancer Biomarkers
      • By Cancer Type:
        • Breast Cancer
        • Lung Cancer
        • Prostate Cancer
        • Kidney Cancer
        • Liver Cancer
        • Other Cancers
      • By End User:
        • Hospitals
        • Academic and Cancer Research Institutes
        • Ambulatory Surgical Centers
        • Cancer Diagnostic Laboratories
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Biomarker Type:
        • Protein Biomarkers
        • Genetic Biomarkers
        • Other Cancer Biomarkers
      • By Cancer Type:
        • Breast Cancer
        • Lung Cancer
        • Prostate Cancer
        • Kidney Cancer
        • Liver Cancer
        • Other Cancers
      • By End User:
        • Hospitals
        • Academic and Cancer Research Institutes
        • Ambulatory Surgical Centers
        • Cancer Diagnostic Laboratories
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Biomarker Type:
        • Protein Biomarkers
        • Genetic Biomarkers
        • Other Cancer Biomarkers
      • By Cancer Type:
        • Breast Cancer
        • Lung Cancer
        • Prostate Cancer
        • Kidney Cancer
        • Liver Cancer
        • Other Cancers
      • By End User:
        • Hospitals
        • Academic and Cancer Research Institutes
        • Ambulatory Surgical Centers
        • Cancer Diagnostic Laboratories
    • Africa
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
      • By Biomarker Type:
        • Protein Biomarkers
        • Genetic Biomarkers
        • Other Cancer Biomarkers
      • By Cancer Type:
        • Breast Cancer
        • Lung Cancer
        • Prostate Cancer
        • Kidney Cancer
        • Liver Cancer
        • Other Cancers
      • By End User:
        • Hospitals
        • Academic and Cancer Research Institutes
        • Ambulatory Surgical Centers
        • Cancer Diagnostic Laboratories
  • Company Profiles
    • BioMerieux S.A. *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bard1 Life Sciences Limited
    • Bio-Rad Laboratories
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Merck & Co., Inc.
    • Qiagen N.V.
    • Thermo Fisher Scientific Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Biomarker Type
      • Market Snippet, By Cancer Type
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Epidemiology 
    • Recent Developments 
    • PEST Analysis
    • Reimbursement Scenario
  4. Global Cancer Biomarkers Market, By Biomarker Type, 2015–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Protein Biomarkers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Genetic Biomarkers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Other Cancer Biomarkers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
  5. Global Cancer Biomarkers Market, By Cancer Type, 2015–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Prostate Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Kidney Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Liver Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Other Cancers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
  6. Global Cancer Biomarkers Market, By End User, 2015–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Academic and Cancer Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
    • Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Million)
  7. Global Cancer Biomarkers Market, By Regions, 2015–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Region, 2016–2025
    • North America
      • Market Size and Forecast, By Biomarker Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Biomarker Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Biomarker Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Biomarker Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Biomarker Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Biomarker Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2015–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2015–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • BioMerieux S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bard1 Life Sciences Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bio-Rad Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Becton, Dickinson and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Qiagen N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Thermo Fisher Scientific Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 33 figures on "Cancer Biomarkers Market - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.